The polo-like kinase Plx1 prevents premature inactivation of the APC(Fizzy)-dependent pathway in the early Xenopus cell cycle.
Members of the polo-like family of protein kinases have been involved in the control of APC (anaphase-promoting complex) during the cell cycle, yet how they activate APC is not understood in any detail. In Xenopus oocytes, Ca2+-dependent degradation of cyclin B associated with release from arrest at second meiotic metaphase was demonstrated to require the polo-like kinase Plx1. The aim of the present study was to examine, beyond Ca2+-dependent resumption of meiosis, the possible role of Plx1 in the control of cyclin degradation during the early mitotic cell cycle. Plx1 was found to be dispensable for MPF to turn on the cyclin degradation machinery. However, it is required to prevent premature inactivation of the APC-dependent proteolytic pathway. Microcystin suppresses the requirement for Plx1 in both Ca2+-dependent exit from meiosis, associated with degradation of both cyclin B and A downstream of CaMK2 activation, and prevention of premature APC(Fizzy) inactivation in the early mitotic cell cycle. These results are consistent with the view that Plx1 antagonizes an unidentified microcystin-sensitive phosphatase that inactivates APC(Fizzy).
Brassac
T
T
Centre de Recherches de Biochimie Macromoléculaire, CNRS UPR 1086, Montpellier, France.
Castro
A
A
Lorca
T
T
Le Peuch
C
C
Dorée
M
M
Labbé
J C
JC
Galas
S
S
D064173:Anaphase-Promoting Complex-Cyclosome; D000818:Animals; D016203:CDC2 Protein Kinase / Q000378:metabolism; D064199:Cdc20 Proteins; D002453:Cell Cycle; D018797:Cell Cycle Proteins / Q000378:metabolism*; D019926:Cyclin B / Q000378:metabolism; D003546:Cysteine Endopeptidases / Q000378:metabolism; D004789:Enzyme Activation; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D008025:Ligases / Q000378:metabolism*; D052998:Microcystins; D009097:Multienzyme Complexes / Q000378:metabolism; D010456:Peptides, Cyclic / Q000494:pharmacology; D010749:Phosphoprotein Phosphatases / Q000037:antagonists & inhibitors / Q000378:metabolism; D046988:Proteasome Endopeptidase Complex; D017346:Protein Serine-Threonine Kinases / Q000235:genetics / Q000378:metabolism*; D015398:Signal Transduction; D013215:Starfish; D013997:Time Factors; D043743:Ubiquitin-Protein Ligase Complexes; D044767:Ubiquitin-Protein Ligases; D014981:Xenopus; D029867:Xenopus Proteins; D000097869:Polo-Like Kinase 1
D064173:Anaphase-Promoting Complex-Cyclosome; D016203:CDC2 Protein Kinase; D064199:Cdc20 Proteins; D018797:Cell Cycle Proteins; D019926:Cyclin B; D003546:Cysteine Endopeptidases; D004791:Enzyme Inhibitors; D008025:Ligases; D052998:Microcystins; D009097:Multienzyme Complexes; D010456:Peptides, Cyclic; D010749:Phosphoprotein Phosphatases; D046988:Proteasome Endopeptidase Complex; D017346:Protein Serine-Threonine Kinases; D043743:Ubiquitin-Protein Ligase Complexes; D044767:Ubiquitin-Protein Ligases; D029867:Xenopus Proteins; C577501:Cdc20 protein, Xenopus; C577488:CDC20 protein, human; C078588:microcystin; C101085:Plk1 protein, Xenopus; D000097869:Polo-Like Kinase 1